Active substance
Results for the substance lorlatinib
2 results
About this active substance
Lorlatinib is a medication used to treat certain types of advanced or metastatic non-small cell lung cancer (NSCLC) with specific mutations in the ALK (anaplastic lymphoma kinase) or ROS1 gene. It is a third-generation tyrosine kinase inhibitor designed to overcome resistance to other ALK/ROS1 inhibitors and to penetrate the central nervous system, making it effective against brain metastases.
Lorlatinib works by blocking the activity of ALK and ROS1 proteins, which drive the growth of cancer cells. It is taken as oral tablets, usually once daily, as directed by a doctor.
Side effects may include increased cholesterol and triglycerides, edema (swelling), peripheral neuropathy, fatigue, cognitive impairment, mood changes, nausea, diarrhea, or weight gain. Patients should be regularly monitored to assess side effects and treatment effectiveness. Lorlatinib is not recommended during pregnancy, as it may harm the fetus.
Lorlatinib works by blocking the activity of ALK and ROS1 proteins, which drive the growth of cancer cells. It is taken as oral tablets, usually once daily, as directed by a doctor.
Side effects may include increased cholesterol and triglycerides, edema (swelling), peripheral neuropathy, fatigue, cognitive impairment, mood changes, nausea, diarrhea, or weight gain. Patients should be regularly monitored to assess side effects and treatment effectiveness. Lorlatinib is not recommended during pregnancy, as it may harm the fetus.
-
-
LORVIQUA 25mg film-coated tablets PFIZER ORIGINAL MEDICINE